Market Closed -
Nasdaq
04:00:00 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
67
USD
|
+2.57%
|
|
+1.96%
|
-6.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,896
|
2,549
|
4,264
|
5,012
|
6,893
|
6,896
|
-
|
-
|
Enterprise Value (EV)
1 |
1,672
|
1,892
|
3,850
|
4,418
|
6,393
|
6,024
|
5,970
|
5,489
|
P/E ratio
|
-12.8
x
|
-9.85
x
|
-15
x
|
-19.5
x
|
-49.1
x
|
-116
x
|
59.8
x
|
19
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
31,282
x
|
112
x
|
50.9
x
|
20
x
|
14.8
x
|
10.4
x
|
7.46
x
|
5.18
x
|
EV / Revenue
|
27,586
x
|
82.9
x
|
45.9
x
|
17.7
x
|
13.8
x
|
9.09
x
|
6.46
x
|
4.12
x
|
EV / EBITDA
|
-10.9
x
|
-8.2
x
|
-13.5
x
|
-16.8
x
|
-40.2
x
|
-75.7
x
|
56.8
x
|
14
x
|
EV / FCF
|
-13.1
x
|
-9.32
x
|
-14.8
x
|
-16.3
x
|
-51.4
x
|
-135
x
|
30.6
x
|
10.2
x
|
FCF Yield
|
-7.66%
|
-10.7%
|
-6.75%
|
-6.13%
|
-1.95%
|
-0.74%
|
3.27%
|
9.83%
|
Price to Book
|
9.77
x
|
3.9
x
|
10.2
x
|
7.65
x
|
11.6
x
|
5.85
x
|
5.17
x
|
3.55
x
|
Nbr of stocks (in thousands)
|
55,261
|
80,158
|
81,463
|
94,705
|
96,238
|
105,575
|
-
|
-
|
Reference price
2 |
34.31
|
31.80
|
52.34
|
52.92
|
71.62
|
67.00
|
67.00
|
67.00
|
Announcement Date
|
3/2/20
|
2/25/21
|
3/1/22
|
3/1/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.0606
|
22.81
|
83.8
|
250.3
|
464.4
|
663
|
924
|
1,331
|
EBITDA
1 |
-153.5
|
-230.7
|
-285.2
|
-263
|
-158.9
|
-79.56
|
105.2
|
391.9
|
EBIT
1 |
-154
|
-231.2
|
-285.7
|
-263.6
|
-159.4
|
-81.21
|
93.36
|
400.2
|
Operating Margin
|
-254,103.04%
|
-1,013.58%
|
-340.9%
|
-105.32%
|
-34.32%
|
-12.25%
|
10.1%
|
30.07%
|
Earnings before Tax (EBT)
1 |
-147.7
|
-227
|
-284.1
|
-256.2
|
-139
|
-61.09
|
109.3
|
438.6
|
Net income
1 |
-147.7
|
-227
|
-284.1
|
-256.3
|
-139.7
|
-56.74
|
110.8
|
368
|
Net margin
|
-243,725.75%
|
-995.07%
|
-339.04%
|
-102.37%
|
-30.08%
|
-8.56%
|
12%
|
27.65%
|
EPS
2 |
-2.680
|
-3.230
|
-3.500
|
-2.720
|
-1.460
|
-0.5756
|
1.121
|
3.528
|
Free Cash Flow
1 |
-128.1
|
-203.1
|
-259.9
|
-271
|
-124.5
|
-44.5
|
195.3
|
539.7
|
FCF margin
|
-211,341.63%
|
-890.12%
|
-310.1%
|
-108.25%
|
-26.8%
|
-6.71%
|
21.14%
|
40.55%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
185.72%
|
137.72%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
176.18%
|
146.65%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
2/25/21
|
3/1/22
|
3/1/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
25.67
|
35
|
55.58
|
71.87
|
87.87
|
95.31
|
110.8
|
126.2
|
132.1
|
144.9
|
158.8
|
171.8
|
187.2
|
192.2
|
210.8
|
EBITDA
1 |
-85.86
|
-72.49
|
-87.75
|
-55.46
|
-47.27
|
-48.26
|
-47.06
|
-29.58
|
-33.96
|
-20.82
|
-27.2
|
-23.3
|
-15.1
|
-
|
-
|
EBIT
1 |
-86
|
-72.66
|
-87.92
|
-55.63
|
-47.41
|
-48.39
|
-47.18
|
-29.71
|
-34.1
|
-20.95
|
-24.29
|
-21.04
|
-15.32
|
-14.53
|
-6.842
|
Operating Margin
|
-335.03%
|
-207.63%
|
-158.19%
|
-77.4%
|
-53.96%
|
-50.78%
|
-42.58%
|
-23.55%
|
-25.81%
|
-14.46%
|
-15.3%
|
-12.24%
|
-8.19%
|
-7.56%
|
-3.25%
|
Earnings before Tax (EBT)
1 |
-85.73
|
-72.11
|
-86.6
|
-53.51
|
-44.03
|
-44.04
|
-42.65
|
-24.22
|
-28.13
|
-14.89
|
-20.87
|
-17.17
|
-6.176
|
-9.675
|
-0.521
|
Net income
1 |
-85.73
|
-72.12
|
-86.6
|
-53.51
|
-44.03
|
-44.05
|
-42.78
|
-24.26
|
-28.58
|
-15.25
|
-20.76
|
-15.87
|
-4.789
|
-10.11
|
-0.521
|
Net margin
|
-333.97%
|
-206.08%
|
-155.82%
|
-74.45%
|
-50.1%
|
-46.22%
|
-38.62%
|
-19.23%
|
-21.63%
|
-10.52%
|
-13.07%
|
-9.24%
|
-2.56%
|
-5.26%
|
-0.25%
|
EPS
2 |
-1.050
|
-0.7800
|
-0.9200
|
-0.5700
|
-0.4500
|
-0.4600
|
-0.4500
|
-0.2500
|
-0.3000
|
-0.1600
|
-0.2030
|
-0.1544
|
-0.0739
|
-0.0933
|
-0.006670
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/10/22
|
8/9/22
|
11/3/22
|
3/1/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/22/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
224
|
657
|
414
|
594
|
500
|
872
|
926
|
1,407
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-128
|
-203
|
-260
|
-271
|
-124
|
-44.5
|
195
|
540
|
ROE (net income / shareholders' equity)
|
-57.6%
|
-53.3%
|
-52.9%
|
-47.7%
|
-22.4%
|
-7.07%
|
5.02%
|
22.3%
|
ROA (Net income/ Total Assets)
|
-48.6%
|
-46.9%
|
-47.1%
|
-41.2%
|
-18.8%
|
-9.23%
|
-5.39%
|
8.81%
|
Assets
1 |
304.2
|
484.3
|
603.6
|
622.4
|
741.4
|
614.5
|
-2,058
|
4,177
|
Book Value Per Share
2 |
3.510
|
8.160
|
5.140
|
6.920
|
6.170
|
11.50
|
13.00
|
18.90
|
Cash Flow per Share
2 |
-2.320
|
-3.270
|
-3.190
|
-2.870
|
-1.300
|
-0.2900
|
1.320
|
2.950
|
Capex
1 |
0.7
|
0.27
|
0.33
|
0.78
|
0.27
|
1.98
|
2.59
|
4.28
|
Capex / Sales
|
1,155.58%
|
1.17%
|
0.39%
|
0.31%
|
0.06%
|
0.3%
|
0.28%
|
0.32%
|
Announcement Date
|
3/2/20
|
2/25/21
|
3/1/22
|
3/1/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
65.32
USD Average target price
90.6
USD Spread / Average Target +38.70% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.45% | 6.9B | | -2.96% | 89.69B | | +2.50% | 41.34B | | -12.01% | 33.72B | | +62.74% | 26.11B | | -19.79% | 14.63B | | -8.58% | 12.84B | | -12.34% | 11.66B | | -43.92% | 11.52B | | +4.27% | 8.92B |
Biopharmaceuticals
|